Patient disposition and cytogenetic response
| Cytogenetic response . | n . | Notes . | |
|---|---|---|---|
| Overall CCgR | 71 | ||
| Time to CCgR ≤ 12 months | 69 | ||
| Time to CCgR > 12 months | 2 | ||
| CML-unrelated death | 2 | Pulmonary embolism (1); NHL (1) | |
| Stable CCgR | 68 | ||
| Loss of CCgR | 1 | CP | |
| Not CCgR | 7 | ||
| AE grade IV | 1 | CP (detailed in text) | |
| Loss of CHR | 1 | CP | |
| ABP | 1 | Allogeneic BMT | |
| No CgR < 6 months (100% Ph+) | 3 | ABP (2); CP (1) | |
| PCgR at 12 months | 1 | Allogeneic BMT | |
| Total | 78 | ||
| Cytogenetic response . | n . | Notes . | |
|---|---|---|---|
| Overall CCgR | 71 | ||
| Time to CCgR ≤ 12 months | 69 | ||
| Time to CCgR > 12 months | 2 | ||
| CML-unrelated death | 2 | Pulmonary embolism (1); NHL (1) | |
| Stable CCgR | 68 | ||
| Loss of CCgR | 1 | CP | |
| Not CCgR | 7 | ||
| AE grade IV | 1 | CP (detailed in text) | |
| Loss of CHR | 1 | CP | |
| ABP | 1 | Allogeneic BMT | |
| No CgR < 6 months (100% Ph+) | 3 | ABP (2); CP (1) | |
| PCgR at 12 months | 1 | Allogeneic BMT | |
| Total | 78 | ||
CCgR indicates complete cytogenetic response; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; CP, chronic phase; AE, adverse event; CHR, complete hematologic response; ABP, accelerated or blastic phase; BMT, bone marrow transplantation; and PCgR, partial cytogenetic response. Bold values indicate totals.